QURE News and Press, uniQure N.V. From 12/19/21

Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...

Pharma/biotech is the most attractive subsector. The most overvalued one is life science tools. IXJ: an alternative to XLV. 10 stocks cheaper than their peers in December. For further details see: IXJ: Healthcare Dashboard For December

Gainers: Adagio (NASDAQ:ADGI) +101%. Kaixin (NASDAQ:KXIN) +34%. Calliditas (NASDAQ:CALT) +25%. Euro Tech Holdings (NASDAQ:CLWT) +19%. Mechel (NYSE:MTL) +17%. Processa (NASDAQ:PCSA) +17%. Versus Systems (NASDAQ:VS) +17%. Assertio (NASDAQ:ASRT) +17%. Zai Lab (NASDAQ:ZLAB) +17%. Petros Pharmaceu...

Gainers: Adagio Therapeutics (NASDAQ:ADGI) +68%, Calliditas Therapeutics (NASDAQ:CALT) +28%, Assertio (NASDAQ:ASRT) +17%, Aptose Biosciences (NASDAQ:APTO) +16%, Arcturus Therapeutics (NASDAQ:ARCT) +15%. Losers: uniQure (NASDAQ:QURE) -25%, Regi...

uniQure (NASDAQ:QURE) announces initial observations on the first four patients enrolled in the lower-dose cohort of its Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease. Shares up 2.5% premarket at $29.47. Two of the four enrolled patients ...

~ Treatment was well tolerated with no significant safety issues related to AMT-130 in first two treated patients through one year of follow-up ~ ~ Neurofilament Light Chain (NfL) rose as expected immediately following surgery and returned to baseline in treated patients ~ ~...

CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for European Patients Living with Hemophilia B PR Newswire KING OF PRUSSIA, Pa. , Dec. 15, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that ...

uniQure (NASDAQ: QURE) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We spoke with uniQure following our recent assumption of coverage of the company's stock and ahead of the upcoming, highly anticipated initial data reado...

CSL Behring and uniQure (NASDAQ:QURE) announces that etranacogene dezaparvovec, an adeno-associated virus five (AAV5)-based gene therapy for the treatment of patients with hemophilia B, achieved the pre-specified primary endpoint of non-inferiority in annualized bleeding rate (ABR) 18-months ...

~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single dose of etranacogene dezaparvovec ~ ~ Etranacogene dezaparvovec also achieved seconda...